

Harvard Bioscience Announces Allocation of Tax Basis for Spin-Off of Harvard Apparatus Regenerative Technology

HOLLISTON, MA, Nov. 13, 2013 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, announced the allocation of tax basis resulting from the tax-free spin-off of Harvard Apparatus Regenerative Technology, Inc. Based on the relative fair market values of the respective companies on November 1, 2013, the first day of trading after distribution, 23.63 percent of a stockholder's pre-distribution tax basis in Harvard Bioscience common stock should be allocated to the shares of common stock in Harvard Apparatus Regenerative Technology received pursuant to the distribution described in the Information Statement of Harvard Apparatus Regenerative Technology dated October 17, 2013.

A copy of the Form 8937, Report of Organizational Actions Affecting Basis of Securities, is available in the Investor Relations section of Harvard Bioscience's website at www.harvardbioscience.com.

About Harvard Bioscience

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research. Our products are sold to thousands of researchers in over 100 countries primarily through our 850 page catalog (and various other specialty catalogs), our website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden and Spain with additional facilities in France and Canada. For more information, please visit our website at www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=6426>

For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site.

Contact:

Jeffrey A. Duchemin
President and Chief Executive Officer
(508) 893-8999

Investor Relations:

Dian Griesel Inc.

Cheryl Schneider

(212) 825-3210

Public Relations:

Dian Griesel Inc.

Susan Forman or Laura Radocaj

(212) 825-3210